Home / Business and Economy / AI Drug Discovery Firm Eyes $50B Valuation
AI Drug Discovery Firm Eyes $50B Valuation
8 Oct
Summary
- Isomorphic Labs is in early funding talks.
- The AI drug discovery startup could reach $50 billion.
- The company originated from Google's DeepMind.
Isomorphic Labs, a pioneering AI-powered drug discovery startup, is currently engaged in preliminary discussions for a new funding round. This initiative could potentially value the company at a remarkable $40 billion or even up to $50 billion.
As a spin-off from Alphabet Inc.'s renowned Google DeepMind, Isomorphic Labs leverages advanced artificial intelligence to accelerate the complex process of identifying and developing new medicines.
The substantial valuation reflects strong investor confidence in the company's innovative approach and its potential to disrupt the pharmaceutical industry.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
